Monopar Therapeutics’ (MNPR) “Overweight” Rating Reiterated at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a report published on Wednesday, Marketbeat.com reports. The firm currently has a $76.00 price target on the stock.

Separately, HC Wainwright raised their price target on shares of Monopar Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd.

Monopar Therapeutics Trading Down 10.6 %

MNPR opened at $40.00 on Wednesday. The stock’s 50-day moving average price is $37.16 and its 200 day moving average price is $22.53. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The firm has a market cap of $244.08 million, a price-to-earnings ratio of -20.30 and a beta of 1.18.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new stake in shares of Monopar Therapeutics during the 4th quarter worth about $23,435,000. Adage Capital Partners GP L.L.C. acquired a new stake in Monopar Therapeutics during the fourth quarter worth approximately $13,182,000. RA Capital Management L.P. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter worth approximately $11,247,000. Point72 Asset Management L.P. purchased a new position in shares of Monopar Therapeutics in the 4th quarter valued at $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Monopar Therapeutics during the 4th quarter worth $2,861,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.